🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementHeadaches on GLP-1 — looking for input

Headaches on GLP-1 — looking for input

robert_kc Wed, Feb 21, 2024 at 11:15 PM 19 replies 2,294 viewsPage 1 of 4
This thread is more than 27 months old. Information may be outdated. Consider searching for more recent discussions.
robert_kc
Member
289
1,234
Oct 2024
Kansas City, MO
Feb 21, 2024 at 11:15 PM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

The bit I cannot resolve on my own is what distinguishes the nausea you can titrate through from the nausea that means stop.

I have searched first, so if this is covered somewhere point me at it and I will read it.

44 14PurityPaulOR, MaxMetOK, MounjBrad and 41 others
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Feb 21, 2024 at 11:25 PM#2

This one has a reasonably settled answer, so here it is. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

43 13sarah_nash92, FitDadDave, RunnerRach and 40 others
Reply Quote Save Share Report
jason_sac26
New Member
34
123
Jan 2026
Sacramento, CA
Feb 21, 2024 at 11:35 PM#3
Dr.AddMedPHL said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

Last edited: Feb 22, 2024 at 1:35 AM
42 12stefan_berlin, Dr.EM_Chicago, pete_RVA and 39 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Feb 21, 2024 at 11:45 PM#4
robert_kc said:
The nausea I get is not really nausea, it is an aversion.

Can confirm the pattern robert_kc describes. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

Last edited: Feb 22, 2024 at 12:45 AM
41 11rachel_ABQ, traveltech_sara, AttorneyGrant and 38 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Feb 22, 2024 at 12:36 AM#5

Adding the clinical framing, because it changes how the question reads. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Last edited: Feb 22, 2024 at 5:36 AM
40 10claudia_zurich, nancy_portland, rick_sfbay and 37 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register